You are here

Blueprint Medicines

The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week

The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week

Yahoo/Benzinga

G1 Therapeutics

Blueprint Medicines

Ironwood Pharmaceuticals

Flag link:

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

Pharmaforum

Blueprint Medicines

Flag link:

Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

Endpoints

Blueprint Medicines

Flag link:

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

Xconomy

Blueprint Medicines

non-small cell lung cancer

Flag link:

Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib

Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib

Pharmaceutical Business Review

Blueprint Medicines

RET-altered cancer

Flag link:

FDA approval tracker: several early decisions in May

FDA approval tracker: several early decisions in May

EP Vantage

Blueprint Medicines

Bristol-Myers Squibb

Flag link:

Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer

Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer

Fierce Pharma

Blueprint Medicines

Flag link:

After a PhIII failure, the FDA delivers Blueprint an expected CRL

After a PhIII failure, the FDA delivers Blueprint an expected CRL

Endpoints

Blueprint Medicines

complete response letter

gastrointestinal stromal tumors

Flag link:

A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close behind

A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close behind

Endpoints

Blueprint Medicines

Flag link:

Blueprint’s voyage ends in disaster

Blueprint’s voyage ends in disaster

EP Vantage

Blueprint Medicines

clinical trials

Flag link:

The crucial data readouts coming soon for small biotechs

The crucial data readouts coming soon for small biotechs

EP Vantage

clinical trials

Blueprint Medicines

TG Therapeutics

Flag link:

Blueprint hits goal in midphase rare disease trial, teeing up pivotal study

Blueprint hits goal in midphase rare disease trial, teeing up pivotal study

Fierce Biotech

Blueprint Medicines

clinical trials

systemic mastocytosis

Flag link:

Go or no go? Esperion's double whammy and a look to priority reviews

Go or no go? Esperion's double whammy and a look to priority reviews

EP Vantage

Esperion Therapeutics

Blueprint Medicines

Agile Therapeutics

Durect Corporation

Flag link:

Racing Blueprint, Lilly drug gets priority review for RET hopeful

Racing Blueprint, Lilly drug gets priority review for RET hopeful

Fierce Biotech

Blueprint Medicines

non-small cell lung cancer

Flag link:

Blueprint gets first approval as FDA backs stomach cancer drug

Blueprint gets first approval as FDA backs stomach cancer drug

Pharmaforum

Blueprint Medicines

Flag link:

Ipsen doubles down on rare bone disease

Ipsen doubles down on rare bone disease

EP Vantage

Blueprint Medicines

Clementia Pharmaceuticals

Flag link:

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

Xconomy

Blueprint Medicines

Flag link:

ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More

ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More

Xconomy

Moderna Therapeutics

Nektar Therapeutics

Blueprint Medicines

Flag link:

ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers

ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers

BioCentury

Blueprint Medicines

RET-altered cancer

Flag link:

Pages